NEUROONE MEDICAL TECHNOLOGIE (NMTC) Stock Fundamental Analysis
USA - NASDAQ:NMTC - US64130M2098 - Common Stock
0.6795 USD
-0.04 (-5.43%)
NMTC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. While NMTC seems to be doing ok healthwise, there are quite some concerns on its profitability. NMTC is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
NMTC had negative earnings in the past year.
NMTC had a negative operating cash flow in the past year.
NMTC had negative earnings in each of the past 5 years.
NMTC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of NMTC (-49.33%) is worse than 66.67% of its industry peers.
The Return On Equity of NMTC (-65.26%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.33% | ||
| ROE | -65.26% | ||
| ROIC | N/A |
ROA(3y)-151.29%
ROA(5y)-173.14%
ROE(3y)-597.5%
ROE(5y)-520.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NMTC has a better Gross Margin (70.14%) than 79.89% of its industry peers.
NMTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.14% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NMTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
NMTC has more shares outstanding than it did 1 year ago.
NMTC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NMTC has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.67, we must say that NMTC is in the distress zone and has some risk of bankruptcy.
NMTC has a Altman-Z score (-1.67) which is comparable to the rest of the industry.
NMTC has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
NMTC has a Debt to Equity ratio of 0.13. This is in the better half of the industry: NMTC outperforms 61.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.67 |
ROIC/WACCN/A
WACC8.67%
2.3 Liquidity
A Current Ratio of 7.13 indicates that NMTC has no problem at all paying its short term obligations.
The Current ratio of NMTC (7.13) is better than 86.24% of its industry peers.
NMTC has a Quick Ratio of 5.80. This indicates that NMTC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NMTC (5.80) is better than 85.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.13 | ||
| Quick Ratio | 5.8 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 67.67% over the past year.
The Revenue has grown by 142.96% in the past year. This is a very strong growth!
The Revenue has been growing by 143.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)67.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.1%
Revenue 1Y (TTM)142.96%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%105.38%
3.2 Future
Based on estimates for the next years, NMTC will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.96% on average per year.
The Revenue is expected to grow by 34.68% on average over the next years. This is a very strong growth
EPS Next Y72.62%
EPS Next 2Y28.64%
EPS Next 3Y19.96%
EPS Next 5YN/A
Revenue Next Year27.11%
Revenue Next 2Y26.81%
Revenue Next 3Y28.25%
Revenue Next 5Y34.68%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NMTC. In the last year negative earnings were reported.
Also next year NMTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NMTC's earnings are expected to grow with 19.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.64%
EPS Next 3Y19.96%
5. Dividend
5.1 Amount
NMTC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:NMTC (11/7/2025, 2:05:36 PM)
0.6795
-0.04 (-5.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners33.63%
Inst Owner Change0.02%
Ins Owners4.18%
Ins Owner Change-1.14%
Market Cap33.98M
Revenue(TTM)9.63M
Net Income(TTM)-5.34M
Analysts85
Price Target2.27 (234.07%)
Short Float %0.12%
Short Ratio0.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.46%
Min EPS beat(2)23.75%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)47.24%
Min EPS beat(4)-34.8%
Max EPS beat(4)158.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-25.92%
Min Revenue beat(2)-43.22%
Max Revenue beat(2)-8.62%
Revenue beat(4)1
Avg Revenue beat(4)-21.92%
Min Revenue beat(4)-88.49%
Max Revenue beat(4)52.66%
Revenue beat(8)2
Avg Revenue beat(8)-19.9%
Revenue beat(12)4
Avg Revenue beat(12)-5.35%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)53.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)11.54%
Revenue NQ rev (1m)17.49%
Revenue NQ rev (3m)10.73%
Revenue NY rev (1m)4.31%
Revenue NY rev (3m)2.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.53 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.15 | ||
| P/tB | 4.18 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.19
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.33% | ||
| ROE | -65.26% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.14% | ||
| FCFM | N/A |
ROA(3y)-151.29%
ROA(5y)-173.14%
ROE(3y)-597.5%
ROE(5y)-520.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 42.13% | ||
| Cap/Sales | 1.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 5.8 | ||
| Altman-Z | -1.67 |
F-Score5
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)158.25%
Cap/Depr(5y)160.45%
Cap/Sales(3y)9.28%
Cap/Sales(5y)12.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.1%
EPS Next Y72.62%
EPS Next 2Y28.64%
EPS Next 3Y19.96%
EPS Next 5YN/A
Revenue 1Y (TTM)142.96%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%105.38%
Revenue Next Year27.11%
Revenue Next 2Y26.81%
Revenue Next 3Y28.25%
Revenue Next 5Y34.68%
EBIT growth 1Y53.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.54%
OCF growth 3YN/A
OCF growth 5YN/A
NEUROONE MEDICAL TECHNOLOGIE / NMTC FAQ
What is the fundamental rating for NMTC stock?
ChartMill assigns a fundamental rating of 3 / 10 to NMTC.
What is the valuation status for NMTC stock?
ChartMill assigns a valuation rating of 0 / 10 to NEUROONE MEDICAL TECHNOLOGIE (NMTC). This can be considered as Overvalued.
What is the profitability of NMTC stock?
NEUROONE MEDICAL TECHNOLOGIE (NMTC) has a profitability rating of 1 / 10.
What is the expected EPS growth for NEUROONE MEDICAL TECHNOLOGIE (NMTC) stock?
The Earnings per Share (EPS) of NEUROONE MEDICAL TECHNOLOGIE (NMTC) is expected to grow by 72.62% in the next year.